Sugi Predict

Sugi Predict / Compounds / SCHEMBL1810835

SCHEMBL1810835

SCHEMBL1810835

NC(=O)Cc1csc(SCC(=O)NC[C@H]2CN(Cc3ccc(Cl)cc3Cl)CCO2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 4/20 0.44
▸ ALDH1A1 P00352 4/20 0.44
▸ DRD4 P21917 2/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ CCR3 P51677 1/20 0.40
▸ NPSR1 Q6W5P4 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ LMNA P02545 2/20 0.35
▸ POLB P06746 1/20 0.35
▸ USP2 O75604 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ CYP2A13 Q16696 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ HTR1A P08908 1/20 0.35
▸ ADRA2A P08913 1/20 0.35
▸ ADORA3 P0DMS8 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1810832 1.00 HPGD (0.44) HPGDALDH1A1DRD4L3MBTL1CCR3
SCHEMBL1811675 0.93 ALDH1A1 (0.46) HPGDALDH1A1DRD4L3MBTL1CCR3
SCHEMBL1811679 0.93 ALDH1A1 (0.46) HPGDALDH1A1DRD4L3MBTL1CCR3
SCHEMBL1811607 0.90 ALDH1A1 (0.50) HPGDALDH1A1DRD4L3MBTL1CCR3
SCHEMBL1811602 0.90 ALDH1A1 (0.50) HPGDALDH1A1DRD4L3MBTL1CCR3
SCHEMBL1812063 0.89 NPSR1 (0.48) HPGDALDH1A1DRD4L3MBTL1NPSR1
SCHEMBL1812067 0.89 NPSR1 (0.48) HPGDALDH1A1DRD4L3MBTL1NPSR1
SCHEMBL1810446 0.88 ALDH1A1 (0.51) HPGDALDH1A1DRD4L3MBTL1CCR3
SCHEMBL1809293 0.88 ALDH1A1 (0.46) HPGDALDH1A1L3MBTL1CCR3POLB
SCHEMBL1809296 0.88 ALDH1A1 (0.46) HPGDALDH1A1L3MBTL1CCR3POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1801108-B9 MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS MITSUBISHI TANABE PHARMA CORP (JP) 2013-11-20 — — EP disclosed
EP-1801108-B1 MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS MITSUBISHI TANABE PHARMA CORP (JP) 2012-11-14 — — EP disclosed
US-7935700-B2 Morpholine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-03 — — US disclosed
US-7935700-B2 Morpholine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-03 — — US disclosed
US-7935700-B2 Morpholine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-03 — — US disclosed
US-20070265257-A1 Morpholine Compound MITSUBISHI PHARMA CORPORATION (JP) 2007-11-15 — — US disclosed
US-20070265257-A1 Morpholine Compound MITSUBISHI PHARMA CORPORATION (JP) 2007-11-15 — — US disclosed
US-20070265257-A1 Morpholine Compound MITSUBISHI PHARMA CORPORATION (JP) 2007-11-15 — — US disclosed
EP-1801108-A1 MORPHOLINE COMPOUND Mitsubishi Pharma Corporation (JP) 2007-06-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265257-A1 Morpholine Compound CCR3, CCR1, CCR4 HPGD 3730/4885ALDH1A1 2661/4885DRD4 768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.